{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:03:53Z","timestamp":1788026633629,"version":"build-2784847793"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T00:00:00Z","timestamp":1664236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["DFF-7026-00052B"],"award-info":[{"award-number":["DFF-7026-00052B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejpb.2022.09.021","type":"journal-article","created":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:13:50Z","timestamp":1664583230000},"page":"170-180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Development of a multiparticulate drug delivery system for in situ amorphisation"],"prefix":"10.1016","volume":"180","author":[{"given":"Tobias Palle","family":"Holm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Kokott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias Manne","family":"Knopp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragna","family":"Berthelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Quodbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"L\u00f6bmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.09.021_b0005","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1021\/acs.molpharmaceut.1c00481","article-title":"Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions","volume":"19","author":"Hiew","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0010","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1021\/mp0600182","article-title":"A Provisional Biopharmaceutical Classification of the Top 200 Oral Drug Products in the United States, Great Britain, Spain, and Japan","volume":"3","author":"Takagi","year":"2006","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0015","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S1056-8719(00)00107-6","article-title":"Drug-like properties and the causes of poor solubility and poor permeability","volume":"44","author":"Lipinski","year":"2000","journal-title":"J. Pharmacol. Toxicol. Methods."},{"key":"10.1016\/j.ejpb.2022.09.021_b0020","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1021\/cg200492w","article-title":"Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals","volume":"11","author":"Babu","year":"2011","journal-title":"Cryst. Growth. Des."},{"key":"10.1016\/j.ejpb.2022.09.021_b0025","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.addr.2016.03.006","article-title":"Physical chemistry of supersaturated solutions and implications for oral absorption","volume":"101","author":"Taylor","year":"2016","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2022.09.021_b0030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S1773-2247(13)50057-8","article-title":"Amorphous drugs and dosage forms","volume":"23","author":"Grohganz","year":"2013","journal-title":"J. Drug Deliv Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.09.021_b0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10865-007-9147-y","article-title":"The impact of medication regimen factors on adherence to chronic treatment: a review of literature","volume":"31","author":"Ingersoll","year":"2008","journal-title":"J. Behav. Med."},{"key":"10.1016\/j.ejpb.2022.09.021_b0040","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1517\/17425247.2011.606808","article-title":"Oral formulation strategies to improve solubility of poorly water-soluble drugs","volume":"8","author":"Singh","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.09.021_b0045","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1124\/pr.112.005660","article-title":"Strategies to address low drug solubility in discovery and development","volume":"65","author":"Williams","year":"2013","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejpb.2022.09.021_b0050","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/A:1007516718048","article-title":"What is the true solubility advantage for amorphous pharmaceuticals?","volume":"17","author":"Hancock","year":"2000","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.09.021_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/js9601896","article-title":"Characteristics and significance of the amorphous state in pharmaceutical systems","volume":"86","author":"Hancock","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0060","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1021\/acs.jpcb.7b10105","article-title":"Glass-transition temperature of the \u03b2-relaxation as the major predictive parameter for recrystallization of neat amorphous drugs","volume":"122","author":"Kissi","year":"2018","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ejpb.2022.09.021_b0065","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jps.10489","article-title":"Physics of amorphous solids","volume":"93","author":"Hilden","year":"2004","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0070","doi-asserted-by":"crossref","unstructured":"T. Vasconcelos, S. Marques, J. das Neves, B. Sarmento, Amorphous solid dispersions: Rational selection of a manufacturing process, Adv. Drug Del. Rev. 100 (2016) 85-101.","DOI":"10.1016\/j.addr.2016.01.012"},{"key":"10.1016\/j.ejpb.2022.09.021_b0075","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ddtec.2011.10.002","article-title":"The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate","volume":"9","author":"Van den Mooter","year":"2012","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.ejpb.2022.09.021_b0080","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1016\/j.xphs.2015.10.008","article-title":"Polymeric Amorphous Solid Dispersions: A Review of Amorphization, Crystallization, Stabilization, Solid-State Characterization, and Aqueous Solubilization of Biopharmaceutical Classification System Class II Drugs","volume":"105","author":"Baghel","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0085","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/jps.21138","article-title":"Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state","volume":"97","author":"Bhugra","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0090","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1021\/mp300386v","article-title":"Construction of drug-polymer thermodynamic phase diagrams using Flory-Huggins interaction theory: identifying the relevance of temperature and drug weight fraction to phase separation within solid dispersions","volume":"10","author":"Tian","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0095","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijpharm.2017.10.051","article-title":"Amorphous solid dispersions and nanocrystal technologies for poorly water-soluble drug delivery - An update","volume":"535","author":"Jermain","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0100","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1021\/acs.molpharmaceut.5b00423","article-title":"Comparative Study of Different Methods for the Prediction of Drug-Polymer Solubility","volume":"12","author":"Knopp","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0105","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1016\/j.apsb.2021.05.014","article-title":"Pharmaceutical amorphous solid dispersion: A review of manufacturing strategies","volume":"11","author":"Bhujbal","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2022.09.021_b0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11030132","article-title":"Overview of the Manufacturing Methods of Solid Dispersion Technology for Improving the Solubility of Poorly Water-Soluble Drugs and Application to Anticancer Drugs","volume":"11","author":"Tran","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.09.021_b0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijpharm.2015.03.053","article-title":"Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulations","volume":"486","author":"D\u00e9muth","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0120","article-title":"Downstream processing of spray-dried ASD with hypromellose acetate succinate \u2013 Roller compaction and subsequent compression into high ASD load tablets","volume":"3","author":"Sauer","year":"2021","journal-title":"Int. J. Pharm.: X."},{"key":"10.1016\/j.ejpb.2022.09.021_b0125","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1039\/c2ce06365d","article-title":"Milling induces disorder in crystalline griseofulvin and order in its amorphous counterpart","volume":"14","author":"Otte","year":"2012","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ejpb.2022.09.021_b0130","doi-asserted-by":"crossref","unstructured":"K.r. Be\u0305rzi\u0146\u0161, S.J. Fraser-Miller, T. Rades, K.C. Gordon, Low-Frequency Raman Spectroscopic Study on Compression-Induced Destabilization in Melt-Quenched Amorphous Celecoxib, Mol. Pharm. 16 (2019) 3678-3686.","DOI":"10.1021\/acs.molpharmaceut.9b00557"},{"key":"10.1016\/j.ejpb.2022.09.021_b0135","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejpb.2012.01.007","article-title":"Can compression induce demixing in amorphous solid dispersions? A case study of naproxen\u2013PVP K25","volume":"81","author":"Ayenew","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0140","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2478\/v10007-007-0023-7","article-title":"Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers","volume":"57","author":"Dhumal","year":"2007","journal-title":"Acta. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0145","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1021\/mp5005788","article-title":"Compression-induced crystallization of amorphous indomethacin in tablets: characterization of spatial heterogeneity by two-dimensional X-ray diffractometry","volume":"12","author":"Thakral","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.addr.2015.12.014","article-title":"Unintended and in situ amorphisation of pharmaceuticals","volume":"100","author":"Priemel","year":"2016","journal-title":"Adv. Drug Del. Rev."},{"key":"10.1016\/j.ejpb.2022.09.021_b0155","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ijpharm.2017.01.035","article-title":"Amorphization within the tablet: Using microwave irradiation to form a glass solution in situ","volume":"519","author":"Doreth","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics12070655","article-title":"Microwave-Induced In Situ Amorphization: A New Strategy for Tackling the Stability Issue of Amorphous Solid Dispersions","volume":"12","author":"Qiang","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.09.021_b0165","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejpb.2017.10.001","article-title":"Influence of PVP molecular weight on the microwave assisted in situ amorphization of indomethacin","volume":"122","author":"Doreth","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0170","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejps.2018.02.012","article-title":"Quantification of microwave-induced amorphization of celecoxib in PVP tablets using transmission Raman spectroscopy","volume":"117","author":"Edinger","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejpb.2020.01.019","article-title":"The influence of drug and polymer particle size on the in situ amorphization using microwave irradiation","volume":"149","author":"Hempel","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0180","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.compositesa.2015.10.035","article-title":"Microwave\u2013material interaction phenomena: Heating mechanisms, challenges and opportunities in material processing","volume":"81","author":"Mishra","year":"2016","journal-title":"Compos. Part A Appl. Sci. Manuf."},{"key":"10.1016\/j.ejpb.2022.09.021_b0185","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1088\/0031-9120\/39\/1\/006","article-title":"Physics of the microwave oven","volume":"39","author":"Vollmer","year":"2003","journal-title":"Phys. Educ."},{"key":"10.1016\/j.ejpb.2022.09.021_b0190","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.msec.2003.09.137","article-title":"Microwave generated nanocomposites for making insoluble drugs soluble","volume":"23","author":"Bergese","year":"2003","journal-title":"Mater. Sci. Eng., C"},{"key":"10.1016\/j.ejpb.2022.09.021_b0195","doi-asserted-by":"crossref","unstructured":"T. Wong, Use of Microwave in Processing of Drug Delivery Systems, Curr. Drug Del. 5 (2008) 77-84.","DOI":"10.2174\/156720108783954842"},{"key":"10.1016\/j.ejpb.2022.09.021_b0200","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/BF02768829","article-title":"The dielectric properties of water in its different states of interaction","volume":"26","author":"Kaatze","year":"1997","journal-title":"J. Solution Chem."},{"key":"10.1016\/j.ejpb.2022.09.021_b0205","doi-asserted-by":"crossref","DOI":"10.1103\/PhysRevE.96.062607","article-title":"Electromagnetic-radiation absorption by water","volume":"96","author":"Lunkenheimer","year":"2017","journal-title":"Phys. Rev. E."},{"key":"10.1016\/j.ejpb.2022.09.021_b0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejps.2016.01.026","article-title":"Influence of PVP\/VA copolymer composition on drug\u2013polymer solubility","volume":"85","author":"Rask","year":"2016","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0215","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1016\/j.xphs.2021.05.010","article-title":"Microwave-Induced in Situ Drug Amorphization Using a Mixture of Polyethylene Glycol and Polyvinylpyrrolidone","volume":"110","author":"Hempel","year":"2021","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0220","article-title":"Microwave induced in situ amorphisation facilitated by crystalline hydrates","volume":"105858","author":"Holm","year":"2021","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0225","article-title":"Supersaturated amorphous solid dispersions of celecoxib prepared in situ by microwave irradiation","volume":"122115","author":"Holm","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121157","article-title":"Investigation into the role of the polymer in enhancing microwave-induced in situ amorphization","author":"Qiang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0235","series-title":"Multiparticulate Drug Delivery: Formulation","first-page":"1","article-title":"Overview of Multiparticulate Systems for Oral Drug Delivery","author":"Rajabi-Siahboomi","year":"2017"},{"key":"10.1016\/j.ejpb.2022.09.021_b0240","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1002\/jps.2600590523","article-title":"Determination of Tablet Strength by the Diametral-Compression Test","volume":"59","author":"Fell","year":"1970","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0245","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the Quantitative Imaging Network","volume":"30","author":"Fedorov","year":"2012","journal-title":"Magn. Reson. Imaging"},{"key":"10.1016\/j.ejpb.2022.09.021_b0250","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/rheumatology\/39.suppl_2.21","article-title":"Celecoxib clinical profile","volume":"39","author":"Tive","year":"2000","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejpb.2022.09.021_b0255","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2022.09.021_b0260","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/030097499750042407","article-title":"Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: What can we expect?","volume":"28","author":"Geis","year":"1999","journal-title":"Scand. J. Rheumatol."},{"key":"10.1016\/j.ejpb.2022.09.021_b0265","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ijpharm.2014.06.060","article-title":"Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs\u2014a fenofibrate case example","volume":"473","author":"Berthelsen","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0270","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/j.1365-2036.2005.02683.x","article-title":"Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging","volume":"22","author":"Schiller","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2022.09.021_b0275","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3109\/10837450.2014.954728","article-title":"A proposal for a drug product Manufacturing Classification System (MCS) for oral solid dosage forms","volume":"20","author":"Leane","year":"2015","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2022.09.021_b0280","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijpharm.2018.05.026","article-title":"Deformation behavior of crystallized mannitol during compression using a rotary tablet press simulator","volume":"547","author":"Tarlier","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0285","article-title":"The use of X-ray microtomography to investigate the microstructure of pharmaceutical tablets: Potentials and comparison to common physical methods","volume":"3","author":"Schomberg","year":"2021","journal-title":"Int. J. Pharm.: X."},{"key":"10.1016\/j.ejpb.2022.09.021_b0290","article-title":"Celecoxib, a COX-II inhibitor, Acta Crystallogr. C","volume":"55","author":"Vasu Dev","year":"1999","journal-title":"Struct. Chem."},{"key":"10.1016\/j.ejpb.2022.09.021_b0295","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/jps.20522","article-title":"Characterization of a novel polymorphic form of celecoxib","volume":"95","author":"Lu","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0300","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s10570-007-9192-2","article-title":"Glass transition temperature and thermal decomposition of cellulose powder","volume":"15","author":"Szcze\u015bniak","year":"2008","journal-title":"Cellulose"},{"key":"10.1016\/j.ejpb.2022.09.021_b0305","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1023\/A:1025490432142","article-title":"Study of thermal behaviour of sugar alcohols","volume":"73","author":"Gomb\u00e1s","year":"2003","journal-title":"J. Therm. Anal. Calorim."},{"key":"10.1016\/j.ejpb.2022.09.021_b0310","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<457::AID-JPS3>3.0.CO;2-G","article-title":"Energy\/Temperature Diagram and Compression Behavior of the Polymorphs of d-Mannitol","volume":"89","author":"Burger","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.09.021_b0315","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1081\/DDC-120021773","article-title":"Preparation and Characterization of Glassy Celecoxib","volume":"29","author":"Paradkar","year":"2003","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0320","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejpb.2016.02.007","article-title":"Influence of polymer molecular weight on in vitro dissolution behavior and in vivo performance of celecoxib:PVP amorphous solid dispersions","volume":"101","author":"Knopp","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0325","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1208\/s12248-016-9865-6","article-title":"Influence of Copolymer Composition on In Vitro and In Vivo Performance of Celecoxib-PVP\/VA Amorphous Solid Dispersions","volume":"18","author":"Knopp","year":"2016","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2022.09.021_b0330","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ejpb.2013.01.010","article-title":"Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state","volume":"84","author":"Arndt","year":"2013","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0335","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejpb.2009.05.009","article-title":"Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling","volume":"73","author":"Shono","year":"2009","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.09.021_b0340","doi-asserted-by":"crossref","first-page":"164","DOI":"10.3390\/pharmaceutics10040164","article-title":"The Influence of Polymers on the Supersaturation Potential of Poor and Good Glass Formers","volume":"10","author":"Blaabjerg","year":"2018","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002168?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122002168?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:50:47Z","timestamp":1760547047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122002168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":68,"alternative-id":["S0939641122002168"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.09.021","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a multiparticulate drug delivery system for in situ amorphisation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}